A PHASE-III RANDOMIZED PLACEBO-CONTROLED STUDY IN 315 PEDIATRIC AND ADULT AUTOLOGOUS OR ALLOGENEIC BONE-MARROW TRANSPLANTATION WITH LENOGRASTIM-5 UG/KG/DAY (GLYCOSYLATED RHU-G-CSF)